Loading organizations...
§ Private Profile · Halifax, NS, Canada
Embolic therapies medical device company using microspheres for interventional radiology, oncology, hypervascular tumors.
ABK Biomedical is a Halifax, Nova Scotia-based medical device company that develops and commercializes image-guided embolic therapies for the treatment of hypervascular tumors. The enterprise produces proprietary radiopaque microsphere technologies, including its Eye90 and Easi-Vue products, which enable interventional radiologists to visually monitor embolization materials during interventional oncology procedures. To advance its clinical pipeline, the venture-backed firm recently initiated its Route90 clinical trial evaluating treatments for patients with unresectable hepatocellular carcinoma. The organization has secured substantial capital to fund these regulatory milestones, including a $30 million Series C round and a subsequent $35 million Series D financing. These equity funding rounds were supported by notable institutional and strategic investors such as HealthCap, Varian Medical Systems, and F-Prime Capital. ABK Biomedical was founded in 2012 by Bob Abraham, Daniel Boyd, and Sharon Kehoe.
ABK Biomedical has raised $95.0M across 3 funding rounds.
ABK Biomedical has raised $95.0M in total across 3 funding rounds.
ABK Biomedical is a clinical-stage medical device company developing innovative embolotherapy products, primarily inorganic polymer microspheres for treating hypervascular tumors like liver cancer.[1][2][3][4] It builds Eye90 microspheres for Y90 radioembolization and Easi-Vue™ embolic microspheres for embolization of arteriovenous malformations and hypervascular tumors, serving interventional radiologists and oncologists treating patients with benign and malignant tumors.[1][2][4] These products solve challenges in tumor targeting and visualization by enabling real-time X-ray imaging during procedures, improving precision dosimetry and outcomes in embolotherapy.[1][3][4] The company has shown strong growth momentum, from pre-clinical R&D to FDA 510(k) clearance for Easi-Vue in 2022, Breakthrough Device Designation for Eye90 in 2023, ISO 13485 certification in 2024, and FDA IDE approval for the pivotal Route90 study in HCC in 2024.[3][4]
Backed by investors like F-Prime Capital since 2019, ABK operates R&D and manufacturing in Halifax, Nova Scotia, with ~38 employees and ~$8M revenue, advancing toward commercialization amid rising demand for imageable embolic therapies.[1][2]
ABK Biomedical was founded in 2012 as a spin-off from Dalhousie University in Halifax, Nova Scotia.[3] The three founders—Interventional Radiologist Robert Abraham, MD, and materials scientists Dr. Daniel Boyd and Dr. Sharon Kehoe—engineered and patented a platform of X-ray visible glass microspheres to address limitations in tumor embolization.[3]
The idea emerged from their expertise in interventional radiology and materials science, leading to early milestones: proprietary microsphere production in 2015, a first-generation delivery system, and a pivot to Y90 radioembolization in 2018.[3] Pivotal moments include transitioning to clinical-stage in 2021 with the first-in-human Eye90 study (first patient treated in 2022), FDA 510(k) for Easi-Vue in 2022, and ongoing regulatory progress.[2][3][4]
ABK stands out in medtech through its focus on imageable microspheres and integrated systems for embolotherapy:
These features enhance developer (physician) experience with better imaging, dosing accuracy, and procedural efficiency.[4][5]
ABK rides the interventional oncology wave, targeting hypervascular liver tumors like HCC amid rising global cancer incidence and demand for minimally invasive therapies over surgery.[1][4] Timing aligns with advances in Y90 radioembolization and embolotherapy, where market forces favor imageable devices for precision medicine—improving survival rates and reducing complications in a $5B+ medtech segment.[1][5]
By partnering with research institutions (e.g., NC State) and investors like F-Prime, ABK influences the ecosystem through clinical data, standardized models, and awards from oncology journals/societies, pushing standards for visualization in IR/IO procedures.[3][4][5] Its Halifax hub bolsters Canada's life sciences cluster, fostering innovation in tumor-targeting tech.[2][3]
ABK is poised for commercialization, with the Route90 pivotal trial underway for Eye90 in unresectable HCC, potentially yielding FDA approval and market entry by 2026-2027.[3][4] Trends like AI-guided imaging, personalized dosimetry, and expanding HCC prevalence (driven by aging populations and NAFLD) will propel growth, alongside partnerships for global scaling.[4][5]
Its influence may evolve from innovator to category leader in imageable embolics, transforming outcomes for liver cancer patients and setting new benchmarks in medtech precision—building directly on its university-born mission to commercialize breakthrough therapies.[1][3]
ABK Biomedical has raised $95.0M across 3 funding rounds. Most recently, it raised $35.0M Series D in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2025 | $35M Series D | JOE Siletto | F Prime Capital, JP Morgan, Himanshu Sharma, Eight Roads Ventures, Ketan Patel, Sante Ventures | Announced |
| Dec 1, 2022 | $30M Series C | Sante Ventures | F Prime Capital, Himanshu Sharma, Eight Roads Ventures, Ketan Patel | Announced |
| Apr 1, 2019 | $30M Series B | F Prime Capital, Varian Medical Systems | F Prime Capital, Himanshu Sharma | Announced |
ABK Biomedical has raised $95.0M in total across 3 funding rounds.
ABK Biomedical's investors include Joe Siletto, F-Prime Capital Partners, JP Morgan, Himanshu Sharma, Eight Roads Ventures, Ketan Patel, Sante Ventures, F-Prime Capital, Varian Medical Systems.